REGENERON PHARMACEUTICALS, INC. (REGN) earnings date
Feb 5, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 30 days, typically, give or take 2 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Fri, Oct 30, 2026 | before open | 30 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | before open | 30 | 8-K |
| Q1 FY2026 | Wed, Apr 29, 2026 | before open | 29 | 8-K |
| Q4 FY2025 | Fri, Jan 30, 2026 | before open | 30 | 8-K |
| Q3 FY2025 | Tue, Oct 28, 2025 | before open | 28 | 8-K |
| Q2 FY2025 | Fri, Aug 1, 2025 | before open | 32 | 8-K |
| Q1 FY2025 | Tue, Apr 29, 2025 | before open | 29 | 8-K |
| Q4 FY2024 | Tue, Feb 4, 2025 | before open | 35 | 8-K |
What they guided beta
| Q3 FY2026 | "Under the terms of the agreement, the Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031. 3 Third Quarter 2026 Financial Results Revenues ($ in millions) Q3 2026 Q3 2025 % Change Net product sales: EYLEA HD - U.S. $ 699 $ 431 62 % EYLEA ® - U.S. 400 681 (41 %) Total EYLEA HD and EYLEA - U.S. 1,099 1,112 (1 %) Libtayo - U.S. 396 219 81 % Libtayo - ROW* 154 146 5 % Total Libtayo - Global 550 365 51 % Praluent ® - U.S. 81 67 21 % Evkeeza ® - U.S. 55 43 28 % Lynozyfic ® - Global 19 1 ** Other products - G" exhibit |
| Q3 FY2026 | "EYLEA U.S. net product sales decreased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to lower sales volumes as a result of continued competitive pressures and the continued transition of patients to EYLEA HD." exhibit |
| Q3 FY2026 | "Other Financial Information GAAP other income (expense), net decreased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to lower net gains on marketable and other securities." exhibit |
| Q3 FY2026 | "In October 2026, the Company declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on December 3, 2026 to shareholders of record as of November 20, 2026. 5 2026 Financial Guidance* The Company's full year 2026 financial guidance consists of the following components: 2026 Guidance Prior Updated GAAP R&D $6.500–$6.635 billion $6.600–$6.735 billion Non-GAAP R&D (a) $5.950–$6.050 billion $6.050–$6.150 billion GAAP SG&A $2.830–$2.960 billion $2.730–$2.860 billion Non-GAAP SG&A (a) $2.500–$2.600 billion $2.400–$2.500 billion GAAP gross margin on net pro" exhibit |
| Q3 FY2026 | "These statements concern, and these risks and uncertainties include, among others, competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates"); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's" exhibit |
| Q2 FY2026 | "Second Quarter 2026 Financial Results Revenues ($ in millions) Q2 2026 Q2 2025 % Change Net product sales: EYLEA HD - U.S. $ 596 $ 393 52 % EYLEA ® - U.S. 412 754 (45 %) Total EYLEA HD and EYLEA - U.S. 1,008 1,147 (12 %) Libtayo - U.S. 343 248 38 % Libtayo - ROW* 146 129 13 % Total Libtayo - Global 489 377 30 % Praluent ® - U.S. 75 66 14 % Evkeeza ® - U.S. 53 41 29 % Lynozyfic ® - Global 17 — ** Total net product sales 1,642 1,631 1 % Collaboration revenue: Sanofi 2,174 1,444 51 % Bayer 276 415 (33 %) Other 6 2 ** Other revenue 193 184 5 % Total revenues $ 4,291 $ 3,676 17 % * Rest of world (" exhibit |
| Q2 FY2026 | "Net product sales of EYLEA in the second quarter of 2026, compared to the second quarter of 2025, were negatively impacted by (i) lower sales volumes, driven by decreased demand, as a result of continued competitive pressures and the continued transition of patients to EYLEA HD, and (ii) a lower net selling price." exhibit |
| Q2 FY2026 | "The interruption did not impact the availability of any of the Company's products. 4 Other Financial Information GAAP other income (expense), net decreased in the second quarter of 2026, compared to the second quarter of 2025, primarily due to lower net gains on marketable and other securities." exhibit |
| Q2 FY2026 | "In July 2026, the Company's board of directors declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on August 31, 2026 to shareholders of record as of August 18, 2026. 2026 Financial Guidance* The Company's full year 2026 financial guidance consists of the following components: 2026 Guidance Prior Updated GAAP R&D $6.450–$6.680 billion $6.500–$6.635 billion Non-GAAP R&D (a) $5.900–$6.100 billion $5.950–$6.050 billion GAAP SG&A $2.860–$3.040 billion $2.830–$2.960 billion Non-GAAP SG&A (a) $2.500–$2.650 billion $2.500–$2.600 billion GAAP gross marg" exhibit |
| Q2 FY2026 | "These statements concern, and these risks and uncertainties include, among others, competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates"); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/REGN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/REGN
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/REGN/"><img src="https://veritasdata.dev/embed/REGN.svg" alt="REGN earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/REGN/)
Script
<script async src="https://veritasdata.dev/embed/REGN.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/REGN"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.